Modality
Cell Therapy
MOA
AHRant
Target
GPRC5D
Pathway
STING
MelanomaMM
Development Pipeline
Preclinical
Feb 2024
→ Jul 2028
PreclinicalCurrent
NCT03383325
1,183 pts·MM
2024-02→2028-07·Recruiting
1,183 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-082.3y awayInterim· MM
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
Preclinical
Recruit…
Catalysts
Interim
2028-07-08 · 2.3y away
MM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03383325 | Preclinical | MM | Recruiting | 1183 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D | |
| Elratapinarof | Halozyme | Phase 2 | C5 |